{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T04:30:49Z","timestamp":1782448249091,"version":"3.54.5"},"reference-count":29,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T00:00:00Z","timestamp":1457222400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Translational Sci"],"published-print":{"date-parts":[[2016,4]]},"abstract":"<jats:p>The propellant\u2010free Combivent Respimat Soft Mist Inhaler (CVT\u2010R) was developed to replace the chlorofluorocarbon\u2010propelled Combivent metered\u2010dose inhaler (CVT\u2010MDI). This steady\u2010state pharmacokinetic (PK) substudy evaluated drug lung\u2010delivery efficiency, using data from two phase III safety and efficacy trials. PK parameters were obtained from well\u2010controlled population PK analyses. Area under the plasma concentration\u2013time curve (AUC), maximum observed plasma concentration (C<jats:sub>max<\/jats:sub>), and minimum observed plasma concentration (C<jats:sub>min<\/jats:sub>) showed systemic exposure to ipratropium bromide and albuterol delivered via the CVT\u2010R was proportional to ex\u2010mouthpiece delivered dose. Although the labeled dose of ipratropium bromide in the CVT\u2010R was half that in the CVT\u2010MDI, the systemic exposure was comparable. No PK interaction for the ipratropium bromide and albuterol Respimat drug components was demonstrated. Ipratropium bromide alone resulted in similar exposure to the combination of ipratropium bromide and albuterol. These results show that CVT\u2010R delivers drug more efficiently to the lung than CVT\u2010MDI.<\/jats:p>","DOI":"10.1111\/cts.12387","type":"journal-article","created":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T13:04:49Z","timestamp":1457269489000},"page":"105-113","source":"Crossref","is-referenced-by-count":3,"title":["Efficiency of Ipratropium Bromide and Albuterol Deposition in the Lung Delivered via a Soft Mist Inhaler or Chlorofluorocarbon Metered\u2010Dose Inhaler"],"prefix":"10.1111","volume":"9","author":[{"given":"TR","family":"MacGregor","sequence":"first","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"ZuWallack","sequence":"additional","affiliation":[{"name":"St. Francis Hospital Medical Center  Hartford Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V","family":"Rubano","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MA","family":"Castles","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Dewberry","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Ltd  Bracknell Berkshire UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ghafouri","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"CC","family":"Wood","sequence":"additional","affiliation":[{"name":"Boehringer Ingelheim Pharmaceuticals Inc  Ridgefield Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,6]]},"reference":[{"key":"e_1_2_9_1_1","unstructured":"Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis management and prevention of chronic obstructive pulmonary disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD). January 2015.http:\/\/www.goldcopd.org\/uploads\/users\/files\/GOLD_Report_2015_Feb18.pdf(accessed September 15 2015)."},{"key":"e_1_2_9_2_1","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. Atrovent HFA (ipratropium bromide HFA) inhalation aerosol full prescribing information. August 2012.http:\/\/docs.boehringer\u2010ingelheim.com\/Prescribing%20Information\/PIs\/Atrovent%20HFA\/10003001_US_1.pdf?DMW_FORMAT=pdf(accessed September 15 2015)."},{"key":"e_1_2_9_3_1","unstructured":"Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Global Initiative for Asthma. April 2015.http:\/\/www.ginasthma.org\/local\/uploads\/files\/GINA_Report_2015_Aug11.pdf(accessed September 15 2015)."},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.105.5.1411"},{"key":"e_1_2_9_5_1","first-page":"902","article-title":"Delivery of ipratropium and albuterol combination therapy for chronic obstructive pulmonary disease: effectiveness of a two\u2010in\u2010one inhaler versus separate inhalers","volume":"8","author":"Chrischilles E.","year":"2002","journal-title":"Am. J. Manag. Care"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1089\/jam.2005.18.273"},{"key":"e_1_2_9_7_1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.2147\/COPD.S3930","article-title":"Higher lung deposition with Respimat Soft Mist inhaler than HFA\u2010MDI in COPD patients with poor technique","volume":"3","author":"Brand P.","year":"2008","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_2_9_8_1","unstructured":"Boehringer Ingelheim International GmbH. Tabulated Study Report: A randomised open label six way cross\u2010over scintigraphic evaluation of the effect of inspiratory flow rate on lung and oropharyngeal deposition with the Respimat inhaler vs. a metered dose inhaler (HFA\u2010MDI) using Berodual in patients with chronic obstructive pulmonary disease (COPD) (ClinicalTrials.govIdentifier:NCT00153075). 24 August 2006.http:\/\/trials.boehringer\u2010ingelheim.com\/content\/dam\/internet\/opu\/clinicaltrial\/com_EN\/results\/215\/215.1364_U06\u20101771_DR.pdf(accessed September 15 2015)."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1089\/jam.2005.18.261"},{"key":"e_1_2_9_10_1","unstructured":"United Nations Environment Programme; Ozone Secretariat. Handbook for the Montreal Protocol on Substances that Deplete the Ozone Layer.http:\/\/ozone.unep.org\/en\/handbook\u2010montreal\u2010protocol\u2010substances\u2010deplete\u2010ozone\u2010layer(accessed September 15 2015)."},{"key":"e_1_2_9_11_1","unstructured":"US Food and Drug Administration. Asthma and COPD inhalers that contain ozone\u2010depleting CFCs to be phased out; alternative treatments available. April 13 2010.http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/2010\/ucm208302.htm(accessed September 15 2015)."},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200464150-00005"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.10.002"},{"key":"e_1_2_9_14_1","first-page":"197","article-title":"Efficacy and safety of tiotropium Respimat SMI in COPD in two 1\u2010year randomized studies","volume":"5","author":"Bateman E.","year":"2010","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.06.004"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2010.01.017"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/COPD.S38577"},{"key":"e_1_2_9_18_1","first-page":"53","article-title":"Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction","volume":"4","author":"Sch\u00fcrmann W.","year":"2005","journal-title":"Treat. Respir. Med."},{"key":"e_1_2_9_19_1","first-page":"375","article-title":"Optimizing nozzles for soft mist inhalers","author":"Spallek M.","year":"2002","journal-title":"Respir. Drug Del."},{"key":"e_1_2_9_20_1","first-page":"379","article-title":"Improved assessment of inhaler device performance using laser diffraction","author":"Wachtel H.","year":"2002","journal-title":"Respir. Drug Del."},{"issue":"1","key":"e_1_2_9_21_1","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1089\/jam.1999.12.Suppl_1.S-19","article-title":"Optimizing the in vitro performance of Respimat","volume":"12","author":"Zierenberg B","year":"1999","journal-title":"J. Aerosol Med."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.21203"},{"key":"e_1_2_9_23_1","unstructured":"Boehringer Ingelheim Pharmaceuticals Inc. COMBIVENT RESPIMAT (ipratropium bromide and albuterol) inhalation spray full prescribing information. October 2014.http:\/\/bidocs.boehringer\u2010ingelheim.com\/BIWebAccess\/ViewServlet.ser?docBase=renetnt&folderPath=\/Prescribing+Information\/PIs\/Combivent+Respimat\/CMVTRSPT.pdf(accessed September 15 2015)."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20269"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00609193"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1136\/thx.36.1.52"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.88.2_Supplement.152S"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2125.2002.01632.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.113.4.957"}],"container-title":["Clinical and Translational Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fcts.12387","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/cts.12387","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cts.12387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T13:14:16Z","timestamp":1695734056000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1111\/cts.12387"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,6]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["10.1111\/cts.12387"],"URL":"https:\/\/doi.org\/10.1111\/cts.12387","archive":["Portico"],"relation":{},"ISSN":["1752-8054","1752-8062"],"issn-type":[{"value":"1752-8054","type":"print"},{"value":"1752-8062","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,6]]}}}